ImmPACT Bio to Present at Jefferies Cell & Genetic Medicine Summit


LOS ANGELES, Calif., September 13, 2023 – ImmPACT Bio USA, Inc. (“ImmPACT BIO”), a clinical-stage company developing transformative logic-gate-based chimeric antigen receptor (CAR) T-cell therapies for treating cancer and autoimmune diseases, today announced that it will participate at the Jefferies Cell & Genetic Medicine Summit, to be held from September 26 -27, 2023 in New York, NY.

Sumant Ramachandra, M.D., Ph.D., ImmPACT Bio’s president and chief executive officer, will participate in a fireside chat on Wednesday, September 27, 2023 at 10:00 AM ET.

Management will also participate in one-on-one investor meetings. To schedule a one-on-one meeting please contact your Jefferies representative.

About ImmPACT Bio
ImmPACT Bio USA, Inc., is a clinical-stage company dedicated to the discovery of transformative chimeric antigen receptor (CAR) T-cell therapies that address key biological challenges in treating cancer and autoimmune diseases. The company’s logic-gate-based CAR T-cell platforms, licensed from University of California, Los Angeles (UCLA) Technology Development Group, are specifically designed to prevent antigen escape, overcome the immunosuppressive tumor microenvironment, and deplete pathogenic B cells. The company’s technology is based on the work of pioneering scientists Yvonne Chen, Ph.D., and Antoni Ribas, M.D., Ph.D., both from UCLA. For more information, visit

Contacts for inquiries or additional information:

For investors:

John Mullaly
LifeSci Advisors

For media:
Kathy Vincent
Greig Communications